In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exact Sciences Buys Time with Genzyme Deal

Executive Summary

On the heels of its rejection of a buyout from Sequenom, Exact Sciences announced a $24.5 million IP licensing deal with Genzyme. The transaction effectively halted Sequenom's takeover effort and bought Exact time for clinical development of a next-generation version of its stool-based colorectal cancer screening test. It'sa hefty deal, but Exact's path to sustainability remains problematic.
Advertisement

Related Content

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2009
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2009
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2009
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2009
Sequenom's Failure Highlights an Underappreciated Risk of Biotech Investing
Sequenom's Failure Highlights an Underappreciated Risk of Biotech Investing
Sequenom Is Improving Prenatal Screening, in Steps
Sequenom Is Improving Prenatal Screening, in Steps
Genomics Squatter

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel